
The company raised its earnings outlook after third-quarter pharmaceutical sales exceeded analysts’ expectations and lowered its full-year debt forecast.
Bayer raised its 2026 adjusted core earnings forecast to between 9.8 billion and 10.3 billion euros on a currency-adjusted basis. The German group cited stronger-than-expected pharmaceutical performance.
The division reported third-quarter sales of 4.68 billion euros, beating analysts’ expectations by 5%, according to a Vara Research poll. CEO Bill Anderson said the business had reached an important turning point in its growth trajectory.
Bayer also lowered its full-year net financial debt forecast by 1 billion euros, to a range of 28 billion to 29 billion euros. As of 09:12 UTC on Tuesday, shares traded at 52.94 euros, up 5.84% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.